TOday’s Movers: Stemline Therapeutics Inc (NASDAQ:STML) Stock Rating Reaffirmed by Analysts at H.C. Wainwright; $34.0 Target Price Indicates 228.50 % Potential

September 17, 2017 - By Peter Erickson

 TOday’s Movers: Stemline Therapeutics Inc (NASDAQ:STML) Stock Rating Reaffirmed by Analysts at H.C. Wainwright; $34.0 Target Price Indicates 228.50 % Potential

Investors sentiment decreased to 1.9 in 2016 Q4. Its down 0.05, from 1.95 in 2016Q3. It dropped, as 7 investors sold Stemline Therapeutics Inc shares while 14 reduced holdings. 14 funds opened positions while 26 raised stakes. 9.13 million shares or 9.47% more from 8.34 million shares in 2016Q3 were reported.

Jpmorgan Chase has invested 0% in Stemline Therapeutics Inc (NASDAQ:STML). State Street invested 0% of its portfolio in Stemline Therapeutics Inc (NASDAQ:STML). Manufacturers Life Com The owns 11,683 shares or 0% of their US portfolio. Baldwin Brothers Inc Ma accumulated 0.01% or 3,100 shares. State Common Retirement Fund owns 31,200 shares for 0% of their portfolio. Wells Fargo Mn reported 13,147 shares or 0% of all its holdings. Credit Suisse Ag reported 11,483 shares. Fmr Limited Company invested in 1.48M shares. Morgan Stanley invested 0% in Stemline Therapeutics Inc (NASDAQ:STML). Carl Domino holds 0.3% or 26,000 shares. Creative Planning reported 0% in Stemline Therapeutics Inc (NASDAQ:STML). Dimensional Fund Limited Partnership stated it has 0% in Stemline Therapeutics Inc (NASDAQ:STML). Savings Bank Of America De owns 0% invested in Stemline Therapeutics Inc (NASDAQ:STML) for 4,547 shares. Columbus Circle Investors invested in 0.01% or 97,629 shares. The Massachusetts-based Rhumbline Advisers has invested 0% in Stemline Therapeutics Inc (NASDAQ:STML).

Stemline Therapeutics Inc (NASDAQ:STML) Rating Reaffirmed

H.C. Wainwright now has a $34.0 price target on shares of Stemline Therapeutics Inc (NASDAQ:STML). The price target would suggest a potential upside of 228.50 % from the last close price of Stemline Therapeutics Inc (NASDAQ:STML). This rating was shown in analysts note on Tuesday, 12 September.

Investors sentiment decreased to 1.9 in 2016 Q4. Its down 0.05, from 1.95 in 2016Q3. It dropped, as 7 investors sold Stemline Therapeutics Inc shares while 14 reduced holdings. 14 funds opened positions while 26 raised stakes. 9.13 million shares or 9.47% more from 8.34 million shares in 2016Q3 were reported.

Jpmorgan Chase has invested 0% in Stemline Therapeutics Inc (NASDAQ:STML). State Street invested 0% of its portfolio in Stemline Therapeutics Inc (NASDAQ:STML). Manufacturers Life Com The owns 11,683 shares or 0% of their US portfolio. Baldwin Brothers Inc Ma accumulated 0.01% or 3,100 shares. State Common Retirement Fund owns 31,200 shares for 0% of their portfolio. Wells Fargo Mn reported 13,147 shares or 0% of all its holdings. Credit Suisse Ag reported 11,483 shares. Fmr Limited Company invested in 1.48M shares. Morgan Stanley invested 0% in Stemline Therapeutics Inc (NASDAQ:STML). Carl Domino holds 0.3% or 26,000 shares. Creative Planning reported 0% in Stemline Therapeutics Inc (NASDAQ:STML). Dimensional Fund Limited Partnership stated it has 0% in Stemline Therapeutics Inc (NASDAQ:STML). Savings Bank Of America De owns 0% invested in Stemline Therapeutics Inc (NASDAQ:STML) for 4,547 shares. Columbus Circle Investors invested in 0.01% or 97,629 shares. The Massachusetts-based Rhumbline Advisers has invested 0% in Stemline Therapeutics Inc (NASDAQ:STML).

Stemline Therapeutics Inc (NASDAQ:STML) Ratings Coverage

Among 4 analysts covering Stemline Therapeutics Inc (NASDAQ:STML), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Stemline Therapeutics Inc has $3400 highest and $11 lowest target. $23.25’s average target is 124.64% above currents $10.35 stock price. Stemline Therapeutics Inc had 9 analyst reports since November 10, 2015 according to SRatingsIntel. H.C. Wainwright maintained Stemline Therapeutics Inc (NASDAQ:STML) rating on Tuesday, September 12. H.C. Wainwright has “Buy” rating and $34.0 target. The stock has “Buy” rating by Jefferies on Monday, June 26. The firm has “Buy” rating by Cowen & Co given on Wednesday, June 14. The firm earned “Outperform” rating on Monday, February 6 by Wedbush. H.C. Wainwright maintained Stemline Therapeutics Inc (NASDAQ:STML) on Monday, June 26 with “Buy” rating. Cowen & Co maintained Stemline Therapeutics Inc (NASDAQ:STML) on Friday, June 23 with “Buy” rating. H.C. Wainwright maintained Stemline Therapeutics Inc (NASDAQ:STML) on Wednesday, August 9 with “Buy” rating.

The stock increased 2.99% or $0.3 on September 15, reaching $10.35. About 417,028 shares traded or 142.69% up from the average. Stemline Therapeutics Inc (NASDAQ:STML) has risen 52.65% since September 17, 2016 and is uptrending. It has outperformed by 35.95% the S&P500.

Wall Street await Stemline Therapeutics Inc (NASDAQ:STML) to release earnings on November, 14. Analysts forecast earnings per share of $-0.62, down exactly $0.06 or 10.71 % from 2014’s $-0.56 EPS. After posting $-0.66 EPS for the previous quarter, Stemline Therapeutics Inc’s analysts now forecast -6.06 % EPS growth.

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering, acquiring, developing and commercializing oncology therapeutics. The company has market cap of $261.65 million. The Firm is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. It currently has negative earnings. SL-401 is a targeted therapy directed to the interleukin-3 receptor (CD123), present on a range of hematologic cancers.

More notable recent Stemline Therapeutics Inc (NASDAQ:STML) news were published by: Globenewswire.com which released: “Stemline Therapeutics to Present SL-401 Updated Data from Stage 1 and 2 of …” on May 18, 2017, also Fool.com with their article: “Why Stemline Therapeutics Inc Stock Is Climbing Today” published on January 06, 2017, Nasdaq.com published: “Stemline Therapeutics to Present SL-801 Phase 1 Data at Upcoming ESMO Congress” on August 30, 2017. More interesting news about Stemline Therapeutics Inc (NASDAQ:STML) were released by: Thestreet.com and their article: “Side Effect Kills Cancer Patient in Stemline Therapeutics Drug Trial; Company …” published on February 02, 2017 as well as Globenewswire.com‘s news article titled: “Stemline Therapeutics to Present at the Rodman & Renshaw 19th Annual Global …” with publication date: September 08, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.